Dr Sharon Discusses How Insurers Have Responded to the Availability of Therapies for RLS
In this video, Denise Sharon, MD, PhD, Clinical Director and Founding Partner, Comprehensive Sleep Medicine Center of the Gulf Coast, discusses how insurers have responded to the availability of therapies and changes in clinical practice guidelines for RLS.
This video was taken on June 4, 2013, at the Sleep 2013 Meeting in Baltimore, MD.
Clinical trials are critical for pushing the oncology field forward, but there is a need for not only more patients to participate in clinical trials, but for a more diverse population, said Howard K. Kaufman, MD, FACS.
California advocates worry that having half its children in Medi-Cal will mean poor access to care. But the real issue may be the growing number of poor children nationwide and the overall effect on Medicaid.
Reports say NIH would receive funds to collect DNA from 1 million volunteers, the National Cancer Institute would get research funds, and FDA would get support to regulate molecular diagnostic tests. The plans need funding from Congress.
The Genetic Information Nondiscrimination Act (GINA) protects most consumers from losing health coverage or their job if they pursue genetic testing. But authors of a new article in The New England Journal of Medicine explore the implications of testing for life, disability and long-term care insurance.
A new private-sector alliance of healthcare systems and payers will dedicate to accelerate the US healthcare system’s transition to value-based models aligned with improving outcomes and lowering costs.